Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16786 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Taku Fujimura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Hemangiosarcoma, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first‐line therapy for CAS, second‐line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane‐switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second‐line chemotherapy were evaluated retrospectively in 50 Japanese taxane‐resistant CAS patients. Although there was no significant difference in progression‐free survival ( P = 0.3528) among the regimens, the incidence of all adverse events (AEs) ( P = 0.0386), as well as severe G3 or more AEs ( P = 0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane‐switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane‐resistant CAS in second‐line therapy based on the safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.
- Department of Dermato-Oncology/Dermatology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Taku Fujimura, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Yumi Kambayashi
Zitieren
APA
Fujimura, T., Maekawa, T., Kato, H., Ito, T., Matsushita, S., Yoshino, K., Fujisawa, Y., Ishizuki, S., Segawa, K., Yamamoto, J., Hashimoto, A., Kambayashi, Y., & Asano, Y. (2023). Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16786
Vancouver
Fujimura T, Maekawa T, Kato H, Ito T, Matsushita S, Yoshino K, et al. Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16786
BibTeX
@article{Fujimura2023,
author = {Fujimura, Taku and Maekawa, Takeo and Kato, Hiroshi and Ito, Takamichi and Matsushita, Shigeto and Yoshino, Koji and Fujisawa, Yasuhiro and Ishizuki, Shoichiro and Segawa, Kojiro and Yamamoto, Jun and Hashimoto, Akira and Kambayashi, Yumi and Asano, Yoshihide},
title = {Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16786}
}
EUVIMED